CN1079243C - Naoxinkang preparation and its producing technology - Google Patents
Naoxinkang preparation and its producing technology Download PDFInfo
- Publication number
- CN1079243C CN1079243C CN97116698A CN97116698A CN1079243C CN 1079243 C CN1079243 C CN 1079243C CN 97116698 A CN97116698 A CN 97116698A CN 97116698 A CN97116698 A CN 97116698A CN 1079243 C CN1079243 C CN 1079243C
- Authority
- CN
- China
- Prior art keywords
- weight
- medicine
- cerebrovascular disease
- treatment cardiovascular
- folium ginkgo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicament for treating and preventing cardio-cerebrovascular diseases and a preparation technology thereof. The medicament is a preparation prepared from raw materials of the following proportion: 5 to 95 parts by weight of ginkgo leaf extract, 5 to 95 parts by weight of leech powder and 10 to 90 parts by weight of unsaturated fatty acid. The preparation can reduce blood fat and cholesterol, soften blood vessels so as to prevent cardiovascular diseases, inhabit platelet aggregation so as to prevent thrombosis, dilate cerebral vessels so as to promote cerebral blood flow, treat and prevent cardio-cerebrovascular diseases so as to prevent apoplexy and senile dementia, and strengthen brain cells so as to prevent brain function decline and improve memory; the preparation has the advantages of simple preparation technology, easy popularization and easy implement.
Description
The present invention relates to the medicament and the production technology thereof of a kind of treatment, prevention cardiovascular and cerebrovascular disease.
Folium Ginkgo extract (Ginkgo Biloba Extract, GBE) Main Ingredients and Appearance is flavone and terpene lactone class material, have blood vessel dilating, cerebral blood flow increasing amount, improve the effect of cerebral blood supply insufficiency, evident in efficacy to disordered brain function, intellectual function decline, senile brain dysfunction, senile dementia etc., but single ginkgo leaf extract preparation is to blood fat reducing, cholesterol, and the effect that promotes congestion to absorb is undesirable.Therefore to make the medicament of a kind of treatment, prevention cardiovascular and cerebrovascular disease, can not adopt single ginkgo leaf extract preparation, also will make up with other compatibility of drugs.
The purpose of this invention is to provide a kind of medicine and production technology thereof for the treatment of cardiovascular and cerebrovascular disease, the medicine of these treatment cardiovascular and cerebrovascular vessel can angiocardiopathy preventing, suppresses platelet aggregation, prevents thrombosis, expansion of cerebral vascular, promote cerebral blood flow, treatment, prevention cardiovascular and cerebrovascular disease, prevention of stroke, senile dementia, strengthen brain cell, prevent the brain function decline, improving memory.The medicine production technology of this treatment cardiovascular and cerebrovascular disease is simple, be easy to promotion and implementation.
For achieving the above object, the present invention is by the following technical solutions: the medicine of this treatment cardiovascular and cerebrovascular disease is the preparation with the feedstock production one-tenth of following weight ratio:
Folium Ginkgo extract: 5-95 (parts by weight)
Hirudo powder: 5-95 (parts by weight)
Wherein the Main Ingredients and Appearance of Folium Ginkgo extract is flavonoid glycoside, terpene lactone, and the content of flavonoid glycoside is 23%-25% (percetage by weight), the content of terpene lactone is 5.5%-6.5% (percetage by weight), its production technology adopts ethanol-resin adsorption method, concentration of ethanol is 15%-75%, and resin is a macroporous adsorbent resin.Used Hirudo is a Hementaria officianalis, and it contains the head of glandula clip, and oven dry is crushed to 60 orders-80 order and gets final product.
The Main Ingredients and Appearance of Folium Ginkgo extract (GBE) is flavonoid glycoside and terpene lactone class material, has blood vessel dilating, the cerebral blood flow increasing amount is improved the function of cerebral blood supply insufficiency, and is evident in efficacy to disordered brain function, intellectual function decline, senile brain dysfunction, senile dementia etc.
The effective constituent that mainly contains of Hirudo is a hirudin, and hirudin is the strongest material of finding so far of resisting blood coagulation activity.Have the inhibition platelet aggregation, blood viscosity lowering improves hemorheological property, eliminates congestion, blood circulation promoting, and the effect of anticoagulant, thromboembolism preventing, shortening euglobulin lysis time, for apoplexy, cerebral blood supply insufficiency disease, curative effect is good.
Innovation of the present invention and distinctive feature are with the Folium Ginkgo extract to be the main Hirudo with different efficacies that cooperates again, make the not available specially good effect product of each single product.
In the present invention, can also add unsaturated fatty acid, make that the medicine of this treatment cardiovascular and cerebrovascular disease is the preparation that the feedstock production with following weight ratio becomes:
Folium Ginkgo extract: 5-95 (parts by weight)
Hirudo powder: 5-95 (parts by weight)
Unsaturated fatty acid: 10-90 part (parts by weight)
Described unsaturated fatty acid has blood fat reducing, cholesterol, and the effect of vessel softening makes the medicine of this treatment cardiovascular and cerebrovascular vessel remove and has the prevention cardiovascular and cerebrovascular disease, suppress platelet aggregation, prevent thrombosis, expansion of cerebral vascular promotes cerebral blood flow, treatment prevention cardiovascular and cerebrovascular disease, prevention of stroke, senile dementia are strengthened brain cell, prevent the brain function decline, outside improving memory and the learning effect, also has the effect of blood fat reducing, cholesterol, vessel softening.
In the present invention, described unsaturated fatty acid comprises linolenic acid, linoleic acid, docosahexenoic acid (Dolosahexanoic Acid is called for short DHA), clupanodonic acid (EicosapentaenoicAcid, be called for short EPA), any one in palmitic olefinic acid, the Palmic acid.The quality of above-mentioned each component all meets national standard.
In the present invention, the medicine of described treatment cardiovascular and cerebrovascular disease can be a kind of in enteric agents, capsule, microcapsule, tablet, electuary, pill, the oral liquid.
In the present invention, the medicine of this treatment cardiovascular and cerebrovascular disease is made through following method:
(1) preparation Folium Ginkgo extract, exsiccant Folium Ginkgo is pulverized, place in the reflux, extract, jar, and to add concentration be that the soak with ethanol of 70% (percetage by weight) is spent the night, water-bath refluxes 2 times again, each 4 hours, merges backflow, filtered while hot, it is 6 that the hydrochloric acid that adds concentration again and be 10% (percetage by weight) in filtrate transfers to pH value, the macroporous resin column that last pre-balance is good, and first is the washing with alcohol decontamination of 15% (percetage by weight) with concentration, reuse concentration is the ethanol elution of 70% (percetage by weight), reclaim ethanol, vacuum concentration is to syrupy shape, lyophilization, obtain Folium Ginkgo extract
(2) the preparation Hirudo powder adopts dry Hirudo, and it contains the head of salivary gland clip, and oven dry is 2 hours under 50 ℃ temperature, is crushed to the 60-80 order again, obtains Hirudo powder,
(3), make the medicine of treatment cardiovascular and cerebrovascular disease with Folium Ginkgo extract, Hirudo powder or add or do not add the above-mentioned weight ratio mixing of unsaturated fatty acid ammonium.
In the medicine production technology of treatment cardiovascular and cerebrovascular disease of the present invention, the medicine of described treatment cardiovascular and cerebrovascular disease can adopt conventional method to make enteric agents, capsule, microcapsule, tablet, electuary, pill, oral liquid.
Preliminary clinical experiment result shows that the medicine of this treatment cardiovascular and cerebrovascular disease weakens for 41 routine cognitive abilitys, but the gerontal patient that self-care ability is still arranged took one month, can improve cognitive ability, improving memory, thinking expression is tending towards normally, and effective percentage reaches 93%.
Show for 27 examples that wood is received, the patient of dementia symptom, treat the medicine of cardiovascular and cerebrovascular disease, took continuously 2 months, then thinking expression is improved significantly, and memory, intellectual function improve comprehensively, and effective percentage reaches 89%.
To 36 routine patients with cerebral hemorrhage, treat the medicine of cardiovascular and cerebrovascular disease, treated one month, except that 4 examples were invalid, all the other 32 examples all were clearly better, and total effective rate reaches 89%, and verbal function, consciousness are expressed and are recovered.
Above-mentioned experimental result explanation, the medicine of this treatment cardiovascular and cerebrovascular disease all has prevention and therapeutical effect for apoplexy, cerebral hemorrhage, senile dementia, senile cerebral disorder.Its curative effect surpasses Western medicine preparation vincamine (effective percentage 47%) commonly used clinically at present and two hydrogen ergotoxine (effective percentage 43%).
Senile hypomnesis, the intellectual function decline, and even dull-witted, reason is a lot, and wherein the physiological function aging is one of principal element, cranial nerve is aging since 20 years old promptly, aging the same as skin along with the mortality of cranial nerve cell, causes the reduction of memory neuron function, cerebral blood flow and oxygen supply deficiency, this also is one of reason of cerebral atrophy, old disordered brain function.Vascular dementia, much more very promptly the embolic dementia is to be caused by reasons such as cerebral hemorrhages, also to see in China.The medicine of treatment cardiovascular and cerebrovascular disease all has specially good effect to above-mentioned various types of alzheimer disease.
Embodiment
One, adopt ethanol-resin method to extract Folium Ginkgo extract (GBE)
The exsiccant Folium Ginkgo of 10kg high-quality is pulverized, put that to add concentration in the reflux, extract, jar be that the soak with ethanol of 70% (percetage by weight) is spent the night, water-bath refluxes 2 times, bath temperature is 80 ℃-90 ℃, each 4 hours, merge backflow, filtered while hot, it is 6 that the hydrochloric acid that adds concentration and be 10% (percetage by weight) in filtrate transfers to pH value, the D101 macroporous resin column that last pre-balance is good, be the ethanol of 15% (percetage by weight) with concentration earlier, the washing decontamination, reuse concentration is the ethanol elution of 70% (percetage by weight), reclaims ethanol, vacuum concentration is to syrupy shape, lyophilization obtains light yellow Folium Ginkgo extract (GBE) 235g, and wherein content of total flavonol glycosides 24%, terpene lactone contents reaches 6%, meets international standard.
Two, Hirudo powder manufactures
Get the exsiccant high-quality Hementaria officianalis of 1kg, it contains the head of glandula clip, after drying 2 hours under 50 ℃ of temperature, be crushed to the 60-80 order, get Hirudo powder 160g, because the active ingredient of Hirudo is a hirudin, mainly be present in the glandula, be used as medicine so only get its effective site head.
Three, according to cooperating or mismatching unsaturated fatty acid, the medicine of this treatment cardiovascular and cerebrovascular disease can carry out the mixing preparation by two kinds of prescriptions.
1, it is as follows not contain the part by weight of medicine each component of treatment cardiovascular and cerebrovascular disease of unsaturated fatty acid:
Folium Ginkgo extract: 5-95 (parts by weight)
Hirudo powder: 5-95 (parts by weight)
2, it is as follows to contain the part by weight of medicine each component of treatment cardiovascular and cerebrovascular disease of unsaturated fatty acid:
Folium Ginkgo extract: 5-95 (parts by weight)
Hirudo powder: 5-95 (parts by weight)
Unsaturated fatty acid: 10-90 (parts by weight)
Formula examples is as follows: to make 1000 brain new capsule is that example describes, and following example 2, example 3, example 4 add different unsaturated fatty acids respectively.
Example 1
Folium Ginkgo: 60g
Hirudo powder: 200g
Adjuvant: 40g
Adjuvant such as starch.Accurately take by weighing above-mentioned three kinds of components, abundant mixing, filling gets final product in 1000 capsules.
Example 2
Folium Ginkgo extract: 40g
Hirudo powder: 180g
Gamma-Linolenic acid: 80g
Accurately take by weighing above-mentioned three kinds of components, abundant mixing, filling gets final product in 1000 capsules.
Example 3 is an example to make 1000 new recovering capsules of brain.
Folium Ginkgo extract: 40g
Hirudo powder: 180g
Docosahexenoic acid (DHA): 80g
Accurately take by weighing above-mentioned three kinds of components, abundant mixing, filling gets final product in 1000 capsules.
Example 4 is an example to make 1000 capsules.
Folium Ginkgo extract: 40g
Hirudo powder: 180g
Clupanodonic acid (DHA): 80g
Accurately take by weighing above-mentioned three kinds of components, abundant mixing, filling gets final product in 1000 capsules.
In sum, the medicine of treatment cardiovascular and cerebrovascular disease of the present invention is based on Folium Ginkgo extract, cooperates Hirudo, unsaturated fatty acid made again, but blood fat reducing, cholesterol, vessel softening, prevention cardiovascular and cerebrovascular disease, suppress platelet aggregation, prevent thrombosis, expansion of cerebral vascular, promote cerebral blood flow, treatment prevention cardiovascular and cerebrovascular disease, prevention of stroke, senile dementia are strengthened brain cell, prevent the brain function decline, improving memory and learning effect.The medicine production technology of this treatment cardiovascular and cerebrovascular disease is simple, is easy to promotion and implementation.
Claims (6)
1, a kind of medicine for the treatment of cardiovascular and cerebrovascular disease is characterized in that: it is to form with following component:
Folium Ginkgo extract: 5-95 weight portion
Hirudo powder: 5-95 weight portion
The content of flavonoid glycoside was 23%-25% (percetage by weight) during wherein said Folium Ginkgo extracted, and the content of terpene lactone is 5.5%-6.5% (percetage by weight).
2, the medicine of treatment cardiovascular and cerebrovascular disease according to claim 1, it is characterized in that: the medicine of this treatment cardiovascular and cerebrovascular disease also comprises the unsaturated fatty acid of 10-90 weight portion, described unsaturated fatty acid comprises linolenic acid, linoleic acid, docosahexenoic acid, clupanodonic acid, any one in palmitic olefinic acid, the Palmic acid.
3, the medicine of treatment cardiovascular and cerebrovascular disease according to claim 1 and 2 is characterized in that: the medicine of described treatment cardiovascular and cerebrovascular disease can be a kind of in enteric agents, capsule, microcapsule, tablet, electuary, pill, the oral liquid.
4, a kind of production technology of the medicine of the described treatment cardiovascular and cerebrovascular disease of preparation claim 1, it is characterized in that: the medicine of this treatment cardiovascular and cerebrovascular disease is made through following method:
(1) preparation Folium Ginkgo extract, exsiccant Folium Ginkgo is pulverized, place in the reflux, extract, jar, and to add concentration be that the soak with ethanol of 70% (percetage by weight) is spent the night, water-bath refluxes 2 times again, each 4 hours, merges backflow, filtered while hot, it is 6 that the hydrochloric acid that adds concentration again and be 10% (percetage by weight) in filtrate transfers to pH value, the macroporous resin column that last pre-balance is good, and first is the washing with alcohol decontamination of 15% (percetage by weight) with concentration, reuse concentration is the ethanol elution of 70% (percetage by weight), reclaim ethanol, vacuum concentration is to syrupy shape, lyophilization, obtain Folium Ginkgo extract
(2) the preparation Hirudo powder adopts dry Hirudo, and it contains the head of salivary gland clip, and oven dry is 2 hours under 50 ℃ temperature, is crushed to the 60-80 order again, obtains Hirudo powder,
(3) Folium Ginkgo extract, Hirudo powder are pressed above-mentioned weight ratio mixing, make the medicine of treatment cardiovascular and cerebrovascular disease.
5, the medicine production technology of treatment cardiovascular and cerebrovascular disease according to claim 4 is characterized in that: in the blending process of described Folium Ginkgo extract, Hirudo powder, also will add the unsaturated fatty acid of 10 1 90 weight portions.
6, according to the medicine production technology of claim 4 or 5 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: the medicine of described treatment cardiovascular and cerebrovascular disease can adopt conventional method to make enteric agents, capsule, microcapsule, tablet, electuary, pill, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116698A CN1079243C (en) | 1997-09-09 | 1997-09-09 | Naoxinkang preparation and its producing technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116698A CN1079243C (en) | 1997-09-09 | 1997-09-09 | Naoxinkang preparation and its producing technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1178698A CN1178698A (en) | 1998-04-15 |
| CN1079243C true CN1079243C (en) | 2002-02-20 |
Family
ID=5174043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97116698A Expired - Fee Related CN1079243C (en) | 1997-09-09 | 1997-09-09 | Naoxinkang preparation and its producing technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1079243C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090944C (en) * | 2000-06-14 | 2002-09-18 | 邓开仲 | Pharmaceutical for preventing and treating senile dementia and depression, and its prepn. process |
| US7501136B2 (en) * | 2003-09-30 | 2009-03-10 | Kao Corporation | Deodorant composition |
| CN108653344A (en) * | 2018-07-23 | 2018-10-16 | 天水市中医医院 | A kind of Chinese medicine composition and preparation method thereof of prophylactic treatment arteriosclerosis |
-
1997
- 1997-09-09 CN CN97116698A patent/CN1079243C/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 黑龙江医药 1998.1.2 黄金伟"通脑灵胶囊药理作用研究" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1178698A (en) | 1998-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1079243C (en) | Naoxinkang preparation and its producing technology | |
| CN1270160A (en) | Refined unsaturated polyfatty acid and calcium salt of unsaturated polyfatty acid as medicinal products and preparing process thereof and preparation | |
| CN1384090A (en) | Extraction process of tanshin general phenolic acid and its prepn and use | |
| CN1151821C (en) | Grape seed preparation and its extracting process | |
| CN1193763C (en) | Rhodiola total tanning matter extract and use for preparing medicine for curing senile dementia | |
| CN1565524A (en) | Medicine for treating senile dementia and its preparing process | |
| CN1660352A (en) | Combination of medication of possessing synergetic effect | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1178699A (en) | Naotaikang preparation and its producing technology | |
| CN1297204C (en) | Prescription and process for Liuwei nourishing tea | |
| CN1899329A (en) | Medicinal composition with blood fat reducing function | |
| CN1636581A (en) | Safflower medicine composition and its prepn process and use | |
| CN1183949C (en) | Medicine for treating thrombus disease | |
| CN1053817C (en) | Acanthopanax root injection freeze-dried powder injection and producing technology for acanthopanax root extract | |
| CN1068043C (en) | Ginkgo leaf liquor and preparation process | |
| CN1314110A (en) | Health drink of purslane and hairyvein agrimonia and its preparing method | |
| CN1264708A (en) | Total safflower yellow and its preparing process and application | |
| CN1140285C (en) | Medicine for treating high blood pressure and preventing cerebral hemorrhage and its preparing method | |
| CN1895392A (en) | Chinese-medicinal preparation for treating cardiovascular and cerebrovascular disease and its making method | |
| CN1251684C (en) | Health care food for relaxing hypertension | |
| KR20000074868A (en) | Composition for sexual dysfunction(3) | |
| CN1628683A (en) | Superficial venules dredging preparation for treating cerebral arteriosclerosis | |
| CN1915250A (en) | Medicinal composition, preparation method and quality control method | |
| CN1931183A (en) | Functional sea food for lowering blood pressure | |
| CN1650891A (en) | Medicinal composition posssessing synergistic action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |